SCHEDULE 13G: CVI Investments and Heights Capital Management Disclose 5.1% Stake in Annovis Bio, Inc.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have disclosed a passive beneficial ownership of 5.1% in Annovis Bio, Inc., totaling 1,000,000 shares of common stock.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, 'Reporting Persons') have filed a Schedule 13G, indicating beneficial ownership in Annovis Bio, Inc.
• The Reporting Persons collectively own 1,000,000 shares of Annovis Bio, Inc. common stock.
• This ownership represents 5.1% of the total outstanding shares of Annovis Bio, Inc.'s common stock.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and exercises shared voting and dispositive power over the reported shares.
• The filing states that the shares were acquired and are held for investment purposes and not to change or influence the control of Annovis Bio, Inc.
• Annovis Bio, Inc. had 19,486,231 shares outstanding as of the completion of a recent offering, as indicated in a Prospectus Supplement filed on February 4, 2025.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the filing indicates a significant institutional investment, which can be seen as a vote of confidence. However, it's a passive investment and doesn't provide operational or financial performance details.

Positives

• A significant institutional investor, CVI Investments, Inc., has taken a substantial 5.1% stake in Annovis Bio, Inc., which can be viewed as a vote of confidence in the company's prospects.
• The investment is managed by Heights Capital Management, Inc., a recognized investment firm, potentially signaling a thorough due diligence process.

Risks

• The filing itself does not detail specific risks related to Annovis Bio, Inc.'s operations or financial health, as it is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Annovis Bio, Inc.'s future performance or strategic direction.

Industry Context

Annovis Bio, Inc. operates in the biotechnology sector. The disclosure of a significant institutional stake by CVI Investments and Heights Capital Management could be interpreted as a positive signal for the company within the broader biotech investment landscape, indicating potential confidence in its drug development pipeline or market position.

Related Party Transactions

• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc., and as such, may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a positive development, potentially increasing confidence in the company's stock.
• The company's management might see this as validation of their strategy and a stable long-term investor.

Key Dates

Keywords

Annovis Bio, CVI Investments, Heights Capital Management, Schedule 13G, beneficial ownership, common stock, institutional investment, biotech, pharmaceutical, equity stake